Compare Invesco DB Agriculture Fund (DBA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs ResMed Inc. — how do they compare? Invesco DB Agriculture Fund trades at $28.35 (market cap $1.33B), while ResMed Inc. trades at $227.51 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 23.9× Invesco DB Agriculture Fund's market cap, and ResMed Inc. pays a 1.17% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and ResMed Inc. for 51 Days on average.
| DBA | RMD | |
|---|---|---|
Market Cap | $1.33B | $31.78B |
Volume | 991,157 | 1,128,382 |
52-Week High | $29.49 | $277.88 |
52-Week Low | $25.44 | $182.82 |
Typical Hold Time | 24 Days | 51 Days |
Sector | — | Health |
Enterprise Value | — | $31.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong YTD performance with 12.4% returns. The technical outlook remains bullish with moving averages signaling strength, though oscillators show neutral momentum. Recent news highlights agricultural ETF outperformance driven by weather risks and geopolitical tensions supporting commodity prices.
The fund's diversified agricultural futures exposure and 3.25% yield provide defensive characteristics amid market volatility. Key risks include high expense ratios (0.85%) and commodity price sensitivity. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish consolidation near all-time highs since 2020.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
